<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898753</url>
  </required_header>
  <id_info>
    <org_study_id>VAL1221-201-16</org_study_id>
    <nct_id>NCT02898753</nct_id>
  </id_info>
  <brief_title>VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Patients With Late-Onset Pompe Disease</brief_title>
  <official_title>A Twelve-Month, Open-Label, Randomized, Parallel Active Control, Single and Repeat Dose, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Delivered Intravenously (IV) in Ambulatory and Ventilator-free Patients With Late-Onset Glycogen Storage Disease-II (GSD-II) (Pompe Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valerion Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valerion Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II study enrolling up to 12 patients in a twelve-month, Open-label, Randomized,
      Parallel Active Control, Single and Repeat Dose, Dose-escalation Study of the Safety,
      Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of
      VAL-1221 Delivered Intravenously (IV) in Ambulatory and Ventilator-free Patients with
      Late-Onset GSD-II (Pompe Disease) Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled in a consecutive manner and randomized to either treatment with
      VAL-1221 or positive control (rhGAA) in cohorts of 4 patients each:

      Part 1 Study Treatment:

      Cohort 1: VAL-1221 3 mg/kg IV (n=3) every other week or control (n=1) Cohort 2: VAL-1221 10
      mg/kg IV (n=3) every other week or control (n=1) Cohort 3: VAL-1221 30 mg/kg IV (n=3) every
      other week or control (n=1)

      Each patient randomized to VAL-1221 will receive 7 every other week IV infusions of VAL-1221
      over 12 weeks. VAL-1221 cohorts will be enrolled in a sequential fashion. Patients randomized
      to rhGAA will be maintained on their current dose and regimen of Myozyme or Lumizyme.

      The first patient in each cohort to receive VAL-1221 will be followed for any safety concerns
      (including infusion related reactions) for a minimum of 48 hours before the remaining
      VAL-1221-treated patients in the cohort receive infusions.

      Once all patients in a cohort have been enrolled and the Data Safety Monitoring Board (DSMB)
      has reviewed safety data from the first 2 infusions in all patients, the next cohort may
      begin enrollment and treatment. A final assessment will occur approximately 2 weeks after the
      last dose of VAL-1221 to collect additional safety data. Safety will be assessed continuously
      throughout the study.

      All patients who complete the study, including those maintained on rhGAA, will be offered
      inclusion in an extension study pending review of safety data by the DSMB and review and
      approval of the extension study by relevant authorities and ethics committees.

      Part 2 Study Design:

      Cohort 1 Patients Patients from Cohort 1 on Part 1of the study who were randomized to
      VAL-1221 will enter Part 2 of the study on the dose with which they were treated (3 mg/kg IV
      every other week). When all patients in Cohort 1 have completed dosing on Part 1 of the study
      and the DSMB has reviewed the Week 12 safety data from that study and determined that there
      are no significant safety issues, the control patient in Cohort 1 may begin treatment with
      VAL-1221 at a dose of 3 mg/kg IV every other week.

      Cohort 2 Patients Patients from Cohort 2 on Part 1 of the study who were randomized to
      VAL-1221 will enter Part 2 of the study on the dose with which they were treated (10 mg/kg IV
      every other week). When all patients in Cohort 2 have completed dosing in Part 1 of the study
      and the DSMB has reviewed the Week 12 safety data from that study and determined that there
      are no significant safety issues, the control patient in Cohort 2 may begin treatment with
      VAL-1221 at a dose of 10 mg/kg IV every other week.

      Cohort 3 Patients Patients from Cohort 3 on Part 1 of the study who were randomized to
      VAL-1221 will enter Part 2 of the study on the dose with which they were treated (30 mg/kg IV
      every other week). No dose increases are anticipated for Cohort 3.

      All patients who complete the study, including those maintained on rhGAA, will be offered
      inclusion in a further extension study pending review of safety data by the DSMB and review
      and approval of the extension study by relevant authorities and ethics committees.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidences of treatment-emergent adverse events</measure>
    <time_frame>Part 1: Baseline through 14 week follow-up; Part 2: Change from Baseline in the Part 1 of the study through Month 12</time_frame>
    <description>Safety and tolerability of VAL-1221 will be determined by assessing treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity outcome measure - incidences of anti-VAL-1221 antibodies</measure>
    <time_frame>Part 1: Baseline through 14 week follow-up; Part 2: Change from Baseline in the Part 1 of the study through Month 12</time_frame>
    <description>Changes from Baseline in antibody formation to VAL-1221</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity outcome measure - incidences of GAA antibodies</measure>
    <time_frame>Part 1: Baseline through 14 week follow-up; Part 2: Change from Baseline in the Part 1 of the study through Month 12</time_frame>
    <description>Changes from Baseline in GAA antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Outcome Measure of VAL-1221 given IV</measure>
    <time_frame>Part 1: Day 1 through 14 week follow-up; Part 2: Change from Baseline in the Part 1 of the study through Month 12</time_frame>
    <description>PK will be assessed by measuring serum levels of VAL-1221</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Outcome Measure of VAL-1221 given IV</measure>
    <time_frame>Part 1: Changes from Baseline to Weeks 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>Changes in urinary hex4 excretion, creatine kinase, muscle glycogen and GAA activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the presence and activity of GAA on muscle biopsy</measure>
    <time_frame>Part 1: Baseline to Week 12</time_frame>
    <description>GAA activity will be measure by biochemical methods to assess changes in GAA activity present in the muscle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the amount of glycogen on muscle biopsy</measure>
    <time_frame>Part 1: Baseline to Week 12</time_frame>
    <description>Glycogen content will be measured biochemically and histologically to determine the changes in glycogen present in the muscle</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from baseline in pulmonary function test (PFT)</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>Pulmonary function testing will be assessed and also compared to prior changes and published results from studies using other forms of GAA</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in 6 Minute Walk Test (6MWT)</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>6MWT will be assessed and also compared to prior changes and published results from studies using other forms of GAA</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in Quantitative Muscle Assessment (QMT)</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>QMT will also be assessed by maximal voluntary isometric contractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Manual Muscle Testing</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>Manual muscle testing will be assessed by Quick Motor Function Test; QMFT</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Timed Functional tests</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>Timed functional tests will be assessed by the GSGC instrument (Gait, stairs, Gower, stand) walk, climbing 4 stairs, supine to standing, sit to stand</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in upper and lower extremity function (UE, LE)</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>UE and LE will be assessed by the Brooke and Vignos scale scales</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in patient reported outcomes in comparison to controls</measure>
    <time_frame>Part 1: Baseline and Week 12; Part 2: Change from Baseline in the Part 1 of the study to Months 6 and 12</time_frame>
    <description>Patient reported health status will be assessed by The Patient Reported Outcomes Measurement Information System (PROMIS) and the Rasch-built Pompe-specific Activity Scale (R-PACT)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>VAL-1221 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive VAL-1221 3 mg/kg IV (n=3) every other week or control (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAL-1221 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive VAL-1221 10 mg/kg IV (n=3) every other week or control (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAL-1221 30 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive VAL-1221 30 mg/kg IV (n=3) every other week or control (n=1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RhGAA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to rhGAA will be maintained on their current dose and regimen of Myozyme or Lumizyme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAL-1221 3 mg/kg</intervention_name>
    <description>VAL-1221 3 mg/kg IV every other week for 12 weeks, inclusive (7 infusions)</description>
    <arm_group_label>VAL-1221 3 mg/kg</arm_group_label>
    <other_name>VAL-1221</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAL-1221 10 mg/kg</intervention_name>
    <description>VAL-1221 10 mg/kg IV every other week for 12 weeks, inclusive (7 infusions)</description>
    <arm_group_label>VAL-1221 10 mg/kg</arm_group_label>
    <other_name>VAL-1221</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAL-1221 30 mg/kg</intervention_name>
    <description>VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive (7 infusions)</description>
    <arm_group_label>VAL-1221 30 mg/kg</arm_group_label>
    <other_name>VAL-1221</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RhGAA</intervention_name>
    <description>Patients randomized to rhGAA will be maintained on their current dose and regimen of Myozyme or Lumizyme</description>
    <arm_group_label>RhGAA</arm_group_label>
    <other_name>Myozyme</other_name>
    <other_name>Lumizyme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients â‰¥18 years

          2. Patient is able and willing to provide informed consent prior to any study procedures
             are performed

          3. Diagnosis of GSDII based on one of the following:

               1. Endogenous cultured skin fibroblast acid alpha glucosidase (GAA) activity &lt;40% of
                  adult normal level

               2. Endogenous whole blood or dried blood spot GAA activity in deficiency range

               3. Genetic analysis showing pathogenic variants in both alleles

          4. Onset of Pompe disease-related symptoms after 1 year of age

          5. Previously treated with Myozyme or Lumizyme for at least 12 months and on a stable
             regimen for the past 6 months

          6. Sexually active patients willing to use an acceptable method of contraception
             (abstinence, oral contraceptives, barrier method with spermicide, or surgical
             sterilization, implanted or injectable contraceptives with a stable dose for at least
             1 month prior to Baseline; hormonal intra-uterine device (IUD) inserted at least 1
             month prior to Baseline) during the study and for 30 days after completion of
             treatment

               1. If patient is female and not considered to be of childbearing potential, she is
                  at least 2 years post-menopause, has undergone a tubal ligation, a total
                  hysterectomy or bilateral oophorectomy

               2. If patient is female and of childbearing potential, she has a negative serum
                  pregnancy test during screening and baseline and must be willing to undergo
                  pregnancy testing during the study

          7. Patient has either &gt;30% and &lt;80% predicted upright forced volume capacity (FVC) or
             patient is able to walk &gt;20% but &lt;80% predicted normal on 6MWT with or without use of
             assistive devices

          8. Patient is willing and able to comply with protocol requirements

        Exclusion Criteria:

          1. Cardiac involvement in first year of life

          2. Anti-GAA antibody titers &gt;1:51,20 at two time points

          3. Prior use of chaperone therapy for GSD-II within the last 12 months

          4. Use of immunosuppressive medication other than glucocorticoids within 6 months prior
             to study enrollment

          5. Use of invasive ventilatory assistance other than BiPAP at night or during periods of
             rest

          6. Has received any investigational medication or has enrolled in any study involving
             investigational drugs or therapies within 30 days prior to first dose of study drug

          7. Start of or change in usual regimen of albuterol or respiratory muscle training within
             30 days prior to first dose of study drug

          8. History of sensitivity to any of the constituents of the study drug

          9. Patient is breastfeeding or planning to become pregnant or breastfeed during the study

         10. Patient has a medical condition or circumstance that, in the opinion of the
             investigator, might compromise the patient's ability to comply with the protocol or
             the patient's well-being or safety

         11. Patient has any condition that, in the view of the investigator, places the patient at
             high risk of poor treatment compliance or of not completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hal Landy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Valerion Therapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Nelken</last_name>
    <phone>617-755-4149</phone>
    <email>michelle.nelken@alopexx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Wencel</last_name>
      <phone>714-456-2525</phone>
      <email>mwencel@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Tahseen Mozaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Austin</last_name>
      <phone>919-668-1347</phone>
      <email>Stephanie.austin@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Priya Kishnani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Woodgate, PhD</last_name>
      <email>p.woodgate@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Robin Lachmann, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSD-II</keyword>
  <keyword>Pompe Disease</keyword>
  <keyword>Glycogen Storage Diseases</keyword>
  <keyword>GAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

